DekaBank Deutsche Girozentrale’s Allogene Therapeutics ALLO Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100,000	Closed	-$1.04M	–	1340
2022 Q3	$1.04M	Buy	100,000 +48,100	+93%	+$654K	﹤0.01%	872
2022 Q2	$606K	Hold	51,900	–	–	﹤0.01%	987
2022 Q1	$485K	Buy	51,900 +700	+1%	+$7.29K	﹤0.01%	1064
2021 Q4	$786K	Buy	51,200 +1,300	+3%	+$22.9K	﹤0.01%	992
2021 Q3	$1.28M	Hold	49,900	–	–	﹤0.01%	846
2021 Q2	$1.26M	Hold	49,900	–	–	﹤0.01%	853
2021 Q1	$1.67M	Buy	49,900 +4,000	+9%	+$135K	0.01%	754
2020 Q4	$1.24M	Buy	45,900 +4,700	+11%	+$153K	﹤0.01%	799
2020 Q3	$1.55M	Buy	+41,200	New	+$1.55M	0.01%	645
2020 Q1	–	Sell	-6,762	Closed	-$178K	–	1059
2019 Q4	$178K	Buy	+6,762	New	+$186K	﹤0.01%	966

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DekaBank Deutsche Girozentrale's ALLO Position: Q4 2022 in Review

DekaBank Deutsche Girozentrale sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 100,000 shares — an estimated $1.04M sold.

DekaBank Deutsche Girozentrale first reported a position in ALLO in Q4 2019 and held it in 10 quarters. The position peaked at $1.67M in Q1 2021. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

DekaBank Deutsche Girozentrale reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 100,000 Allogene Therapeutics shares in Q4 2022, an estimated $1.04M.
DekaBank Deutsche Girozentrale first reported a position in Allogene Therapeutics in Q4 2019 and held it in 10 quarters.
DekaBank Deutsche Girozentrale's Allogene Therapeutics position peaked at $1.67M in Q1 2021.
168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2022, filed 1 Feb 2023.